

The Effect of Oxcarbazepine on Epilepsy, Neuropathic pain, Inflammatory Pain and Morphine Tolerance

Wonyeong Jeong¹, Hyun Cheol Yang¹ and Jong Yeon Park^{2*}

¹Department of Anesthesiology and Pain Medicine, Asan Medical Center, Korea

²Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

ARTICLE INFO

Received Date: July 02, 2022

Accepted Date: July 18, 2022

Published Date: July 22, 2022

KEYWORDS

Oxcarbazepine
Carbamazepine
Schizophrenia

Copyright: © 2022 Jong Yeon Park et al., Pharmaceutical Sciences And Biomedical Analysis Journal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation for this article: Wonyeong Jeong, Hyun Cheol Yang and Jong Yeon Park. The Effect of Oxcarbazepine on Epilepsy, Neuropathic pain, Inflammatory Pain and Morphine Tolerance. Pharmaceutical Sciences And Biomedical Analysis Journal. 2022; 4(1):127

Corresponding author:

Jong Yeon Park,
Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-3867; Fax: +82-2-3010-6958;
Email: jonyeon_park@amc.seoul.kr

ABSTRACT

Oxcarbazepine has various actions. It can be used for treatment of epilepsy, trigeminal neuralgia, and diabetic neuropathy. In the animal study, oxcarbazepine has some evidence that it could be used for treatment of inflammatory pain and morphine tolerance.

INTRODUCTION

The Effect of Oxcarbazepine to Epilepsy

Epilepsy is a chronic non-communicable disease of the brain and it affects people of all ages. According to guidelines by the American Academy of Neurology and American Epilepsy Society [1], for the treatment of patients with newly diagnosed epilepsy, standard anticonvulsants such as carbamazepine, phenytoin, valproic acid, valproate semisodium, phenobarbital, or newer anticonvulsants including gabapentin, lamotrigine, oxcarbazepine or topiramate can be prescribed. Carbamazepine is used primarily in the treatment of epilepsy and neuropathic pain [2]. It is also used in schizophrenia, generalized seizures and as a second-line agent in bipolar disorder [2]. Common side effects of carbamazepine are nausea and drowsiness [2]. Serious side effects of carbamazepine may include skin rashes, decreased bone marrow function, suicidal thoughts, or confusion [2].

Oxcarbazepine is a structural analogue of carbamazepine, and it was developed in an effort to avoid side effects of carbamazepine and its active metabolites, and to improve the tolerability and pharmacokinetic profile of the carbamazepine [3]. Oxcarbazepine and carbamazepine appear to be similarly effective and well tolerated, however, oxcarbazepine may have fewer side effects, except for more risk of hyponatremia compared to carbamazepine [4].

The Effect of Oxcarbamazepine for the Treatment of Neuropathic Pain

In 1994, the definition of neuropathic pain has been published by the International Association for the Study of Pain (IASP) as "pain initiated or caused by a primary lesion, dysfunction, or transitory perturbation of the peripheral or central nervous system" [5]. However, in 2011, the definition of neuropathic pain was changed as 'pain caused by a lesion or disease of the somatosensory nervous system' by IASP [6]. Comparing the old and new definitions of neuropathic pain, there are two important changes in the new version: (1) the word "dysfunction" has been removed and (2) a lesion or disease affecting the nervous system has been specified to be a lesion or disease of the somatosensory system.

Neuropathic pain manifests primarily as allodynia (pain caused by a stimulus that does not normally provoke pain) and hyperalgesia (an increased response to a stimulus that is normally painful). The mechanisms responsible for the induction of nerve injury-induced neuropathic pain, however, are not entirely clear [7].

Treatment options for neuropathic pain can be divided into pharmacological and nonpharmacological (e.g., interventional, physical, and psychological therapies) approaches.

(1) First-line pharmacological treatments for neuropathic pain

Amitriptyline (10-150 mg/day) is recommended as a first-line drug and its major side effects are dry mouth, constipation, urinary retention, and orthostatic hypotension [8]. gabapentin/gabapentin ER/enacarbil (1200-3600 mg/day tid) and pregabalin (300-600 mg/day bid), are the first-choice drugs [9]. The major side effects are dizziness, sedation, and peripheral swelling. Carbamazepine (200-400 mg/day) and oxcarbazepine (300-600 mg/day) are recommended for trigeminal neuralgia [10].

(2) Second-line pharmacological treatments for neuropathic pain

The opioid analgesics tramadol/tramadol ER (200-400 mg/day bid) and tapentadol (50-600 mg/day) are second-choice drugs [9]. The most common side effects are nausea, vomiting, and constipation [11]. Lidocaine (5%) plaster and capsaicin (8%) patch are recommended as second-choice drugs [9].

(3) Third-Line Drug Treatments for neuropathic pain

The strong opioids, morphine (10-120 mg/day) and oxycodone (10-120 mg/day), are recommended as third-line pharmacotherapeutic options. The neurotoxin, Botulinum Toxin subcutaneously (50-200 IU: every three months), is a third-choice treatment option.

Oxcarbazepine is a kind of the sodium channel blocker, and it's efficacious in peripheral neuropathic pain patients with the irritable nociceptor phenotype. The irritable nociceptor phenotype was defined as having LOG1, LOG2, LOG3, L2G1, L2G2, and L2G3. Thus, in the patients with the irritable nociceptor phenotype, upregulation of sodium channels on nociceptors is proposed to be an important pain-generating mechanism, and they are characterised by having cold and warmth detection thresholds within the normal [12].

Trigeminal neuralgia is a long-term pain disorder that affects the trigeminal nerve. The trigeminal nerve responsible for sensation in the face and motor functions such as biting and chewing. The typical form results in episodes of severe, sudden, shock-like pain in one side of the face that lasts for seconds to a few minutes and these episodes can occur over a few hours. The atypical form results in a constant burning pain that is less severe. Episodes may be triggered by any touch to the face [13]. The treatment of trigeminal neuralgia should begin either with carbamazepine or with oxcarbazepine [14].

Diabetic neuropathy is very broad and heterogeneous term which encompasses a number of mono and polyneuropathies as well as plexopathies and radiculopathies. There is limited data regarding the efficacy of carbamazepine, oxcarbazepine and topiramate. Oxcarbazepine may have some effect, but we cannot be confident that the results [15].

The Effect of Oxcarbazepine for the Inflammatory Pain

In the animal study [16], male Wistar rats (180-220g) were included. Predrug hyperalgesia was obtained before intraperitoneal drug administration. Inflammatory hyperalgesia was induced 30min after intraperitoneal drug injection by intraplantar concanavalinA (0.8mg/paw) administration into the right hind paw. Postdrug hyperalgesia was measured at 90, 150, 210, 270, and 330min after drug administration. Control animals received the same volume of intraperitoneal vehicle instead of test compound. The antihyperalgesic activity of carbamazepine (10-40 mg/kg; intraperitoneal) and oxcarbazepine (40-160 mg/kg; intraperitoneal) was determined by modified 'paw-pressure' test, using the apparatus for evaluating the force exerted by rat hind paws in order to determine right/left differences. A comparable pattern of antihyperalgesic effect of carbamazepine and oxcarbazepine was observed, and carbamazepine was about three times more potent than oxcarbazepine.

The Effect of Oxcarbazepine for the Morphine Tolerance

Morphine is one of the most effective drugs currently used for pain management. However, its prolonged administration for chronic pain produces tolerance to the analgesic effects, and thus limiting their therapeutic potential. In the animal study [17], male Sprague-Dawley rats (200-250 g) were included. Tail-flick assay was performed for the measurement of acute nociceptive sensitivity. To induce the morphine tolerance, the

dose of morphine 15µg was administered to intrathecal space through a polyethylene (PE-10) catheter implanted to the lumbar enlargement for 7 days. Oxcarbazepine (100 µg) was intrathecally co-administered with morphine for 7 days to evaluate the antitolerance effect of Oxcarbazepine. The decrease in morphine effect was completely blocked throughout the entire 7-day period.

CONCLUSION

Oxcarbazepine is a structural analogue of carbamazepine. In addition, oxcarbazepine and carbamazepine appear to be similarly effective and well tolerated, however, oxcarbazepine may have fewer side effects. Oxcarbazepine is a kind of the sodium channel blocker, and it's efficacious in peripheral neuropathic pain patients with the irritable nociceptor phenotype. Carbamazepine and oxcarbazepine are recommended for trigeminal neuralgia. Oxcarbazepine may have some effect for the treatment of diabetic neuropathy. In the animal study, Oxcarbazepine presented anti-inflammatory effect and attenuating effect against morphine tolerance.

REFERENCES

- Andres MK, Eric A, David G, Cynthia H, Blaise B, et al. (2018). Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 91: 74-81.
- Alrashood ST. (2015). Carbamazepine. *Profiles Drug Subst Excip Relat Methodol*. 41: 133-321.
- Ambrósio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. (2002). Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. *Neurochem Res*. 27: 121-130.
- Koch MW, Polman SK. (2009). Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. *Cochrane Database Syst Rev*. 4. CD006453.
- Merskey H, Bogduk N, editors. (1994). Task force on taxonomy of the International Association for the Study of Pain: classification of chronic pain. Description of pain syndromes and definitions of pain terms. Seattle: IASP Press. 210-213.
- Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, et al. (2011). A new definition of neuropathic pain. *Pain*. 152: 2204-2205.
- Choi YS, Jun IG, Kim SH, Park JY. (2013). Intrathecal lamotrigine attenuates mechanical allodynia and suppresses microglial and astrocytic activation in a rat model of spinal nerve ligation. *Yonsei Med J*. 54: 321-329.
- Kerstman E, Ahn S, Battu S, Tariq S, Grabis M. (2013). Neuropathic pain. *Handb Clin Neurol*. 110: 175-187.
- Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, et al. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol*. 14: 162-173.
- Cruccu G, Truini A. (2017). A review of neuropathic pain: from guidelines to clinical practice. *Pain Ther*. 6: 35-42.
- Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. (2019). The neuropathic pain: an overview of the current treatment and future therapeutic approaches. *Int J Immunopathol Pharmacol*. 33: 2058738419838383.
- Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, et al. (2014). The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. *Pain*. 155: 2263-2273.
- Cruccu G, Di Stefano G, Truini A. (2020). Trigeminal Neuralgia. *N Engl J Med*. 383: 754-762.
- Cruccu G. (2017). Trigeminal Neuralgia. 23: 396-420.
- Kaur S, Pandhi P, Dutta P. (2011). Painful diabetic neuropathy: an update. *Ann Neurosci*. 18: 168-175.
- Tomić MA, Vučković SM, Stepanović-Petrović RM, Ugrešić N, Prostran MŠ, et al. (2004). The anti-hyperalgesic effects of carbamazepine and oxcarbazepine are attenuated by treatment with adenosine receptor antagonists. *Pain*. 111: 253-260.
- Jun IG, Park JY, Choi YS, Im SH. (2009). Effect of intrathecal oxcarbazepine on rat tail flick test-determined morphine tolerance. *Korean J Anesthesiol*. 57: 337-341.